AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?

AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?

Science Founded on Unique Insights, Powered by Groundbreaking Research

A collection of research papers, scientific publications and presentations relevant to our platform, processes, and products.

Clicking on one of the links below will direct you away from AlloVir's website.

AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing these links as a convenience, and these links do not imply AlloVir’s endorsement of any material on the website you are about to visit.

Title

Publication

Date

The publications above are provided for historical purposes only. AlloVir disavows any obligation to update the information contained in these publications after the date of their issuance.

ash

year-2021

Posoleucel (ALVR105), an Off-the-Shelf, Multivirus-Specific T-Cell Therapy, for the Prevention of Viral Infections Post-HCT: Results from an Open-Label Cohort of a Phase 2 Trial

ASH

December 11, 2021

id-week

year-2021

Allogeneic, Off-the-Shelf, SARS-CoV-2-specific T cells Demonstrate Reactivity Against Emerging Variant Strains

ID Week

September 29, 2021

tct

year-2021

Allogeneic, Off-the-Shelf Multi-Virus Specific T-Lymphocytes for the Treatment of Virus-Associated Hemorrhagic Cystitis in the Post-HSCT Setting

TCT

March 1, 2021

tct

year-2021

Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High-Risk Patients with COVID-19

TCT

March 1, 2021

tct

year-2021

Economic and Clinical Burden of Virus-Associated Hemorrhagic Cystitis in Pediatric and Adult Patients Following Allogeneic Hematopoietic Stem Cell Transplantation

TCT

March 1, 2021

tct

year-2021

Economic Burden and Health Resource Utilization Associated with Dsdna Virus Infections in Allogeneic Hematopoietic Cell Transplantation Recipients

TCT

March 1, 2021

tct

year-2021

Economic and Clinical Burden of Virus-Associated Hemorrhagic Cystitis in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation in the United States

TCT

February 25, 2021

ash

year-2020

Treatment of Severe, Drug-Refractory Viral Infections with Allogeneic, Off-the-Shelf Multi-Virus Specific T Cells in Patients Following HSCT: Results from a Phase 2 Study

ASH

December 7, 2020

ash

year-2020

Using Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High Risk Patients with COVID-19

ASH

December 7, 2020

ash

year-2020

Economic and Clinical Burden of Virus-Associated Hemorrhagic Cystitis in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation

ASH

December 7, 2020

id-week

year-2020

Economic and Clinical Burden of Respiratory Virus infections in Allogeneic Hematopoietic Cell Transplantation Recipients

ID Week

October 21, 2020

id-week

year-2020

Health Resource Utilization and Costs Associated with Multi-Virus infection after Allogeneic Hematopoietic Cell Transplantation

ID Week

October 21, 2020

blood-advances

year-2019

"Mini” bank of only 8 donors supplies CMV-directed T cells to diverse recipients

Blood Advances

September 1, 2019

haematologica

year-2019

Rapid generation of multivirus-specific T lymphocytes for the prevention and treatment of respiratory viral infections

Haematologica

April 1, 2019

current-opinion-infections-diseases

year-2018

Infusion of Cytotoxic T Lymphocytes for the Treatment of Viral Infections in Hematopoetic Stem Cell Transplant Patients

Current Opinion Infections Diseases

August 1, 2018

journal-of-clinical-oncology

year-2017

Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation

Journal of Clinical Oncology

August 1, 2017

immunological-reviews

year-2014

Antiviral T-cell Therapy

Immunological Reviews

April 1, 2014

We Treat Individuals at High Risk

Our allogeneic, off-the-shelf VST candidates benefit patients with T cell deficiencies, including transplant recipients, immunocompromised cancer patients, the elderly, and the very young, who are at a higher risk of the devastating consequences of viral diseases.

BK Virus
Cytomegalovirus
Adenovirus
Epstein-Barr Virus

Human Herpesvirus-6
Parainfluenza Virus
Human Metapneumovirus
Influenza Virus

Respiratory Syncytial Virus
SARS-CoV-2
Hepatitis B Virus

Bladder

Severe hemorrhagic cystitis
Urinary obstruction
Cystectomy

Brain

Severe encephalitis
Seizure
Memory defect
Progressive Multifocal Leukoencephalopathy

Kidneys

Nephritis
Acute/chronic renal failure
End stage renal disease

Lungs

Pneumonia
Bronchitis
Respiratory failure

Eyes

Retinitis
Blindness

Liver

Chronic hepatitis
Liver cirrhosis
Hepatocellular Carcinoma

Small/Large Intestine

Colitis
Ulceration / perforation
Intestinal bleeding

Malignancy

Kaposi sarcoma
Primary Effusion
Lymphoma (PEL)

AlloVir is the global leader in developing VST immunotherapies

We develop highly innovative, allogeneic, off-the-shelf, virus-specific T cell (VST) therapies designed to prevent and treat life-threatening viral diseases.

Our Pipeline

Our allogeneic, off-the-shelf VST therapy candidates target 12 different devastating viruses as treatment or prevention.

Our Platform

Our proprietary platform develops allogeneic, off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies.

Our People

We are united in purpose around a singular mission to prevent and defeat life-threatening viral diseases.